Menu Search
Equities

Mink Therapeutics Inc

INKT:NAQ

Mink Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.7501
  • Today's Change0.015 / 2.03%
  • Shares traded40.83k
  • 1 Year change-36.97%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 20:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Mink Therapeutics Inc had revenues remain flat at 0.00, though the company grew net income from a loss of 27.99m to a smaller loss of 22.46m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-152.35%
Return on equity--
Return on investment-4,151.28%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Mink Therapeutics Inc fell by 16.27m. Cash Flow from Investing was negative at 73.56k, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 15.76m for operations while cash used for financing totalled 407.17k.
Cash flow per share-0.4795
Price/Cash flow per share--
Book value per share-0.4202
Tangible book value per share-0.4202
More ▼

Balance sheet in USDView more

Mink Therapeutics Inc uses little or no debt in its capital structure.
Current ratio0.9336
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.